6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine

6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine Basic information
Product Name:6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine
Synonyms:6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine;Tofacitinib Related Compound 23;5H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6,7-dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-;Azilsartan medoxomil impurity319;Tofacitinib Hydrogenation Impurities;(6,7-Dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-(4-methyl-piperidin-3-yl)-amine;Tofatinib Impurity 17;N-Methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine (Tofacitinib Impurity)
CAS:1812890-23-5
MF:C13H21N5
MW:247.34
EINECS:
Product Categories:
Mol File:1812890-23-5.mol
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine Structure
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical Properties
Boiling point 435.9±45.0 °C(Predicted)
density 1.137±0.06 g/cm3(Predicted)
solubility Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
form Solid
pka9.48±0.10(Predicted)
color Off-White to Pale Yellow
Safety Information
MSDS Information
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine Usage And Synthesis
UsesN-Methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine is an intermediate (reagent) in the preparation of Tofacitinib analog compounds.
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine Preparation Products And Raw materials
N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine Tofacitinib Impurity 2 Tofacitinib Related Compound (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyriMidin-4-yl)(Methyl)aMino)-4-Methylpiperidin-1-yl)-3-oxopropanenitrile Tofacitinib Impurity 19 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide R-afatinib (3R,4R)-N,1,4-trimethyl-N-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidin-3-amine Tofacitinib Impurity 20 (S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine (3R,4R)-3-[(6-amino-4-pyrimidinyl)methylamino]-4-methyl-β-oxo-1-Piperidinepropanenitrile (3R,4R)-N,4-dimethyl-piperidin-3-amine TF-A 2-amino-4-fluoro-5-nitrobenzoic acid Ethyl S-4-chloro-3-hydroxybutyrate

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.